Liquid Biopsies for Assessing Metastatic Melanoma Progression.
Liquid Biopsies for Assessing Metastatic Melanoma Progression.
复制标题
DOI：
10.1615/critrevoncog.2016016075
复制
发表时间：
2016
影响因子：
--
通讯作者：
Hoon DS
中科院分区：
文献类型：
--
作者：
Huynh K;Hoon DS
在过去的几十年中，黑色素瘤的基因组生物标志物领域发生了巨大的变化。尽管之前的大部分焦点都集中在肿瘤组织的分子评估上，但循环肿瘤细胞（CTC）和无细胞循环肿瘤DNA（ctDNA）作为癌症患者中的“液体活检”的来源提供了作为评估肿瘤进展、鉴定治疗靶点和评估对治疗的临床反应的方法的有希望的潜力。血液生物标志物测定具有非侵入性的优点，允许在连续时间范围内动态评估疾病，并有助于解决组织采样偏差和肿瘤异质性的问题。然而，仍然存在用于分离和检测CTC和ctDNA的各种技术和工艺，并且尚未建立标准化方法。尽管存在这些挑战，但多项研究已经证明了基于血液的基因组生物标志物测定的临床预后效用。随着下一代测序和全基因组ctDNA分析的出现，这无疑将提高对肿瘤进展的理解，有助于确定新的治疗靶点，并改善对治疗反应和耐药性发展的监测。
The field of genomic biomarkers in melanoma has evolved dramatically in the past few decades. Whereas much of the prior focus has been on molecular assessment of tumor tissue, circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) as sources of a “liquid biopsy” in cancer patients provide promising potential as a method to assess tumor progression, identify targets for therapy, and to evaluate clinical response to treatment. Blood biomarker assays have the advantage of being non-invasive, allow for dynamic evaluation of disease over a serial time frame, and help to address the issue of tissue sampling bias and tumor heterogeneity. However, there still remains an assortment of technologies and techniques to isolate and detect CTCs and ctDNA and a standardized method is yet to be established. Despite these challenges, multiple studies have already demonstrated the clinical prognostic utility of blood-based genomic biomarker assays. With the advent of next generation sequencing and genome-wide ctDNA analysis, this will undoubtedly lead to an improved understanding of tumor progression, help to identify new targets for treatment, and improve monitoring of treatment response and development of resistance.